香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的中小型公司提供一個上市的市場。有意投 資的人士應瞭解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場波動風險， 同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確 表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告由密迪斯肌控股有限公司（「本公司」）董事（「董事」）共同及個別負全責，其中載有遵照香港聯合交易所有限 公司GEM證券上巿規則（「GEM上巿規則」）所規定有關本公司的資料。董事在作出一切合理查詢後確認，就彼等所 深知及確信，本報告所載資料在各重大方面均屬準確完備，且無誤導或欺詐成份，亦無遺漏其他事項致使本報告 或其所載任何陳述產生誤導。 目錄 | 公司資料 | 3 | | --- | --- | | 主席報告 | 4 | | 管理層討論 ...

Economic Environment - The company reported a challenging economic environment with slow recovery in Hong Kong, leading to cautious consumer spending and reduced local consumption[10] - The overall economic conditions have pressured the retail and service sectors in Hong Kong, impacting the company's operations[10] - The medical skin care industry remains competitive, facing rising operational costs and suppressed local demand[10] Financial Performance - The group’s revenue for the year ended March 31, 2025, decreased by HKD 4.0 million or 8.2% to HKD 45.1 million from HKD 49.1 million for the year ended March 31, 2024[18] - The total sales revenue, including prepaid treatment plan receipts, recorded a slight decline of HKD 1.4 million or 2.9%, from HKD 50.9 million to HKD 49.5 million[18] - The group reported a loss attributable to equity holders of HKD 3.4 million for the year ended March 31, 2025, an increase of HKD 0.4 million or 10.8% compared to HKD 3.0 million for the year ended March 31, 2024[19] - Basic loss per share for the period was HKD 0.85, an increase of 10.4% from HKD 0.77 in the previous year[19] - Other income increased by HKD 0.8 million or 78.9% to HKD 1.8 million for the year ending March 31, 2025, primarily due to a reversal of provisions and increased bank interest income[22] Operational Strategies - Cost-saving measures and operational optimizations have been implemented to enhance long-term business sustainability and performance[10] - The group is actively exploring deeper market penetration and offering a wider range of services, particularly focusing on anti-aging and preventive care[15] - The group is implementing cost-saving measures and improving operational efficiency to address rising operational costs and intense industry competition[18] - The group plans to continue seeking strategic growth opportunities to strengthen its competitive advantage and create long-term value for shareholders[15] Technological Advancements - The company is focused on technological advancements, continuously introducing advanced solutions to improve service quality and competitiveness[11] - The introduction of the "Titan Lift" laser treatment technology, which utilizes three laser wavelengths, aims to enhance skin firmness and elasticity[16] - The group is assessing how to integrate artificial intelligence into its services for more precise and data-driven skincare solutions[15] Human Resources - The medical team consists of experienced professionals, with most doctors having nearly or over 20 years of clinical experience, reinforcing the company's reputation as a trusted provider[11] - Employee costs decreased by HKD 0.7 million or 3.0% to HKD 23.9 million for the year ending March 31, 2025, due to reduced bonuses and salaries[24] - The group employed 27 full-time and 16 part-time employees as of March 31, 2025, compared to 29 full-time and 14 part-time employees in 2024[51] Corporate Governance - The company has established a remuneration committee to review and recommend compensation policies for directors and senior management, considering company and individual performance[78] - The independent non-executive directors have confirmed their independence, and their re-election was approved at the 2024 annual general meeting[75] - The company has established three committees: the audit committee, the remuneration committee, and the nomination committee, to oversee specific aspects of the company's affairs[126] - The board consists of four executive directors and three independent non-executive directors as of March 31, 2025[108] Environmental, Social, and Governance (ESG) Initiatives - The company is committed to fulfilling its corporate social responsibility and being accountable to individuals, communities, and the environment[164] - The company’s environmental, social, and governance report covers its performance in these areas during the operational period from April 1, 2024, to March 31, 2025[160] - The company has established key performance indicators for measurable comparisons in its environmental and social performance[162] - Total greenhouse gas emissions for 2025 were 48,045 kg CO2 equivalent, a decrease of 5.1% from 50,636 kg in 2024[179] Risk Management - The group faces foreign currency risk primarily from purchases denominated in currencies other than its operating currency, mainly USD[49] - The group has not implemented any interest rate hedging policies but will monitor interest rate risks closely[50] - The company has established a shareholder communication policy to provide timely and comprehensive information to shareholders and investors, which is reviewed at least annually[147] Shareholder Information - The company has not proposed a final dividend for the year ending March 31, 2025, consistent with 2024[58] - The company aims to ensure that the new share option plan aligns with the long-term growth interests of the group[87] - The company has no knowledge of any direct or indirect competition from its directors or major shareholders as of March 31, 2025[81]

行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-20.99倍，行业中值0.36倍。密迪斯 肌市盈率-20.39倍，行业排名第68位；其他巨星医疗控股（02393.HK）为0.33倍、京玖康疗 （00648.HK）为0.38倍、永胜医疗（01612.HK）为4.39倍、环球医疗（02666.HK）为4.51倍、瑞慈医疗 （01526.HK）为5.15倍。 6月20日，截至港股收盘，恒生指数上涨1.26%，报23530.48点。密迪斯肌（08307.HK）收报0.17港元/ 股，上涨11.84%，成交量13.2万股，成交额2万港元，振幅16.45%。 最近一个月来，密迪斯肌累计跌幅9.52%，今年来累计涨幅1.33%，跑输恒生指数15.84%的涨幅。 财务数据显示，截至2024年9月30日，密迪斯肌实现营业总收入2014.06万元，同比减少9.05%；归母净 利润-183.33万元，同比增长4.24%；毛利率82.16%，资产负债率88.7%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 2025年6月23日，披露2024财年年报 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为 ...

MEDIC SKIN MEDICSKI IN EMFACE' ��� EMFACE* EXION EXIO MFACE® EXION" E EM �33 MFACE® EXION EXION- 6 20 MFAC E 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）的特色 GEM的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的中小型公司 提供一個上市的市場。有意投資的人士應瞭解投資於該等公司的潛在風險，並應經 過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之 證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市 場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 本報告由密迪斯肌控股有限公司（「本公司」）董事（「董事」）共同及個別負全責，其中 載有遵照香港聯合交易所有限公司GEM證券上巿規則（「GEM上巿規則」）所規定有關 本公司的資料。董事在作出一切合理查詢後確認 ...

Financial Performance - The company reported a revenue of HKD 22,334 thousand for the six months ended September 30, 2024, a decrease of 9.0% compared to HKD 24,555 thousand in the same period last year[8]. - The pre-tax loss for the period was HKD 2,038 thousand, slightly improved from a loss of HKD 2,145 thousand in the previous year, indicating a reduction in losses[8]. - The basic loss per share was HKD 0.51, compared to HKD 0.54 in the same period last year, reflecting a 5.6% improvement in per-share performance[11]. - The company has reported a total comprehensive loss of HKD 2,048 thousand for the period, compared to HKD 2,123 thousand in the previous year, showing a slight improvement[10]. - The company recorded a pre-tax loss of HKD 12,188,000 for the six months ended September 30, 2024, compared to a pre-tax loss of HKD 12,511,000 in the same period of 2023, showing a slight improvement of about 2.6%[29]. - The loss attributable to the company's owners for the six months ended September 30, 2024, was HKD 2.0 million, a decrease of HKD 0.1 million or 4.2% from HKD 2.1 million in the same period of 2023[50]. - The company recorded a loss attributable to owners of HKD 2.0 million for the six months ending September 30, 2024, a decrease of HKD 0.1 million or 4.2% from a loss of HKD 2.1 million in the previous year[62]. Revenue Breakdown - Revenue from medical consultation services decreased to HKD 535,000 from HKD 589,000, a decline of approximately 9.2% year-over-year[22]. - Revenue from prescription and dispensing services fell to HKD 4,112,000 from HKD 4,749,000, representing a decrease of about 13.4%[22]. - Revenue from treatment services decreased to HKD 17,687,000 from HKD 19,217,000, a decline of approximately 7.9%[22]. - The revenue breakdown includes medical consultation services at HKD 0.5 million (2.4%), prescription and dispensing services at HKD 4.1 million (18.4%), and treatment services at HKD 17.7 million (79.2%) of total revenue[50]. Assets and Liabilities - Total assets as of September 30, 2024, amounted to HKD 45,972 thousand, an increase from HKD 40,060 thousand as of March 31, 2024[13]. - The company's net asset value decreased to HKD 5,533 thousand from HKD 7,581 thousand as of March 31, 2024, representing a decline of 27.0%[13]. - Inventory levels increased to HKD 4,799 thousand from HKD 4,315 thousand, indicating a rise of 11.2% in stock held[13]. - The company has a total current liability of HKD 37,461 thousand, up from HKD 31,740 thousand, reflecting a 17.5% increase in obligations[13]. - Non-current liabilities include long service payment obligations of HKD 799 thousand, which increased from HKD 739 thousand[13]. - The company's current liabilities net value was HKD 3.1 million, primarily arising from contract liabilities of HKD 20.3 million, which are expected to be fulfilled without cash outflow[19]. - The total equity as of September 30, 2024, was HKD 5.5 million, down from HKD 7.6 million as of March 31, 2024[65]. - The debt-to-equity ratio as of September 30, 2024, was 162.7%, indicating a significant increase in leverage compared to the previous period[65]. Cash Flow - The company reported a net cash inflow from operating activities of HKD 982,000 for the six months ended September 30, 2024, compared to HKD 2,831,000 in the same period of 2023, indicating a decrease of approximately 65.3%[16]. - The company’s cash and cash equivalents increased to HKD 12,938,000 as of September 30, 2024, compared to HKD 3,351,000 at the end of the same period in 2023, indicating a significant increase of approximately 286.5%[16]. - The company’s financing activities generated a net cash inflow of HKD 5,134,000 for the six months ended September 30, 2024, compared to a net cash outflow of HKD 3,850,000 in the same period of 2023[16]. Operational Efficiency - The company continues to focus on enhancing its operational efficiency and exploring new market opportunities to drive future growth[8]. - The group has implemented cost-saving measures and enhanced operational efficiency to improve performance amid challenges in the market[48]. Staffing and Governance - The company employed 29 full-time and 14 part-time employees as of September 30, 2024, maintaining the same staffing levels as of March 31, 2024[76]. - The board of directors is led by Dr. Jiang, who serves as both the chairman and CEO, ensuring alignment with the company's business strategy[86]. - The audit committee has been established in accordance with GEM listing rules and consists of three independent non-executive directors[96]. - The audit committee reviewed the unaudited interim financial statements for the six months ending September 30, 2024, and confirmed compliance with applicable accounting standards and GEM listing rules[96]. - The interim financial statements have been adequately disclosed as per regulatory requirements[96]. Shareholder Information - As of September 30, 2024, Dr. Jiang holds a controlling interest in 274,865,400 shares, representing 69.28% of the issued share capital of the company[78]. - Topline Worldwide Limited, wholly owned by Dr. Jiang, is the registered holder of the 274,865,400 shares, which are considered beneficially owned by Dr. Jiang[81]. - No other directors or key executives hold any interests or short positions in the company's shares or related securities as of September 30, 2024[80]. Dividends and Share Options - The board did not recommend an interim dividend for the six months ended September 30, 2024, consistent with the previous year[32]. - The old share option scheme, adopted on December 3, 2014, will expire on December 3, 2024, with no unexercised options remaining as of March 31, 2024[91]. - A new share option scheme was adopted on September 27, 2024, to attract and retain talent, with a total of 39,673,600 options available under the new plan[93]. - No share options were granted, exercised, vested, lapsed, or cancelled during the six months ending September 30, 2024[94]. Other Information - There were no significant events occurring after the reporting period[44]. - The company has not purchased, sold, or redeemed any of its listed securities during the six months ending September 30, 2024[89]. - The company has no significant investments or capital asset plans as of September 30, 2024[68][69]. - The company does not have any major contingent liabilities as of September 30, 2024[74]. - There are no known direct or indirect competitive businesses or interests held by directors or controlling shareholders as of September 30, 2024[84]. - The company has complied with the corporate governance code as of September 30, 2024, with no known deviations[85].

Financial Performance - The company reported a revenue of HKD 49.1 million for the fiscal year ending March 31, 2024, representing a 7.9% increase from HKD 45.5 million in the previous fiscal year[8]. - The company recorded a loss attributable to shareholders of HKD 3.0 million, a decrease of 13.8% compared to a loss of HKD 3.5 million in the previous year[8]. - Basic loss per share for the year was HKD 0.77, down 13.5% from HKD 0.89 in the previous year[8]. - The company experienced over 20% revenue growth in the first half of the fiscal year, although this momentum slowed down later in the year[7]. - The group's revenue increased by HKD 3.6 million or 7.9% to HKD 49.1 million for the year ending March 31, 2024, compared to HKD 45.5 million for the previous year[18]. - Revenue from medical consultation services, prescription and dispensing services, and treatment services accounted for 2.3%, 19.2%, and 78.5% of total revenue, respectively[15]. Operational Challenges - The company continues to face intense competition and rising operational costs but remains committed to maintaining high standards and competitiveness in its services and products[8]. - The company acknowledges the impact of a slowing Chinese economy and high interest rates on business confidence, affecting consumer spending behavior[7]. - The group anticipates continued challenges due to adverse economic conditions but aims to adapt and monitor market changes proactively[17]. - The company has implemented cost-saving measures and improved operational efficiency to enhance performance amid challenges[8]. Strategic Focus - The company aims to strategically expand and strengthen its market share in Hong Kong and mainland China while enhancing service and product quality[11]. - The company is focused on exploring and launching new services and products to increase market share and identify new business opportunities[9]. - The group introduced new treatment technologies, including EMFACE® Submentum and SYLFIRM X™, enhancing its service offerings[13]. Employee and Cost Management - Employee costs increased by HKD 1.4 million or 6.2% to HKD 24.6 million for the year ending March 31, 2024, due to increased salaries and performance bonuses[22]. - Other expenses rose by HKD 1.4 million or 18.4% to HKD 9.0 million, aligning with the increase in revenue[25]. - Inventory costs for the years ending March 31, 2024, and 2023 were HKD 9.7 million and HKD 8.9 million, representing 19.8% and 19.5% of total revenue, respectively[20]. Shareholder Relations - The company expresses gratitude to shareholders, business partners, suppliers, and customers for their support during the year[9]. - The company did not recommend any final dividend for the year ending March 31, 2024, consistent with 2023[60]. - The company’s distributable reserves as of March 31, 2024, amounted to HKD 1.1 million[71]. Governance and Compliance - The audit committee has reviewed the audited consolidated financial statements for the year ending March 31, 2024, ensuring compliance with applicable accounting standards and GEM listing rules[99]. - The company has adopted corporate governance practices in line with GEM listing rules and has not deviated from the corporate governance code during the fiscal year[108]. - The company has established three committees: the audit committee, the remuneration committee, and the nomination committee, to oversee specific aspects of corporate governance[133]. Environmental, Social, and Governance (ESG) Initiatives - The company’s environmental, social, and governance report covers operations from April 1, 2023, to March 31, 2024, focusing on its medical skin care centers in Hong Kong, which contribute nearly all of its revenue[174][175]. - The total greenhouse gas emissions for the group in 2024 were 50,636 kg CO2 equivalent, a decrease from 52,136 kg in 2023, representing a reduction of approximately 2.9%[198]. - The group has established key performance indicators for measuring its environmental and social performance, ensuring consistency in statistical methods for meaningful comparisons[178]. - The group aims to integrate sustainability into its core business values and continuously review progress against ESG-related goals[183]. Risk Management - The company has implemented a risk management and internal control system, which was reviewed by the audit committee for effectiveness[136]. - The board believes that the internal control measures are adequate to effectively monitor business operations for the fiscal year ending March 31, 2024[153]. - The company has a risk management framework that includes processes for risk identification, analysis, assessment, treatment, and monitoring[151].

Financial Performance - The company reported a revenue of HKD 49.1 million for the fiscal year ending March 31, 2024, representing a 7.9% increase from HKD 45.5 million in the previous fiscal year[13]. - The company recorded a loss attributable to owners of HKD 3.0 million, a decrease of HKD 0.5 million or 13.8% compared to a loss of HKD 3.5 million for the fiscal year ending March 31, 2023[13]. - Basic loss per share for the year was HKD 0.77, a reduction of 13.5% from HKD 0.89 in the previous year[13]. - The company experienced over 20% revenue growth in the first half of the fiscal year, although this momentum slowed down later in the year[13]. - The company noted increased competition within the industry and rising operational costs[14]. - The company's revenue increased by HKD 3.6 million or 7.9% to HKD 49.1 million for the year ended March 31, 2024, compared to HKD 45.5 million for the previous year[24]. Operational Challenges - The company faced challenges due to a slowdown in the Chinese economy, high interest rates, and a stagnant local real estate and stock market[13]. - Consumer sentiment has become more cautious, impacting the company's industry negatively[13]. - Cost-saving measures and operational efficiency improvements have been implemented to address the challenges faced by the company[14]. - The management anticipates ongoing challenges due to adverse economic conditions but remains committed to adapting strategies to maintain service quality and market position[23]. Revenue Breakdown - Revenue from medical consultation services, prescription and dispensing services, and treatment services accounted for 2.3%, 19.2%, and 78.5% of total revenue, respectively[21]. Employee and Operational Costs - Employee costs increased by HKD 1.4 million or 6.2% to HKD 24.6 million for the year ended March 31, 2024, primarily due to increased salaries and performance bonuses[28]. - Other expenses increased from HKD 7.6 million for the year ending March 31, 2023, to HKD 9.0 million for the year ending March 31, 2024, representing an increase of HKD 1.4 million or 18.4%[31]. - The company has implemented cost-saving measures to improve operational efficiency amid rising operational costs and intense competition[18]. Financial Position - The total equity of the company as of March 31, 2024, was HKD 7.6 million, down from HKD 10.6 million as of March 31, 2023[35]. - The company had cash and bank balances of HKD 6.9 million as of March 31, 2024, compared to HKD 5.0 million as of March 31, 2023, with over 96% held in HKD[35]. - Operating cash generated for the year ending March 31, 2024, was HKD 11.0 million, up from HKD 4.3 million for the previous year[37]. - The company had no interest-bearing borrowings as of March 31, 2024, resulting in a debt-to-equity ratio of zero[35]. - The company has unused bank financing of HKD 18.0 million under the SME Financing Guarantee Scheme as of March 31, 2024[37]. Governance and Compliance - The company has maintained compliance with all relevant laws and regulations without any significant violations during the fiscal year ending March 31, 2024[63]. - The company has adopted the corporate governance code as per GEM Listing Rules Appendix C1 and has complied with it for the year ending March 31, 2024[114]. - The audit committee has reviewed the audited consolidated financial statements for the year ending March 31, 2024, ensuring compliance with applicable accounting standards and GEM listing rules[105]. - The company has established a shareholder communication policy to ensure timely and comprehensive information is provided to shareholders and investors, which is reviewed at least annually[165]. Sustainability and ESG - The environmental, social, and governance report covers the company's performance in these areas for the period from April 1, 2023, to March 31, 2024, focusing on its medical skin care services in Hong Kong[180]. - The company aims to integrate sustainability into its core business values and will continue to review progress based on environmental, social, and governance-related goals[189]. - The company has complied with the "comply or explain" provisions of the environmental, social, and governance reporting guidelines for the fiscal year ending March 31, 2024[190]. - The company conducted an annual materiality assessment to identify and understand stakeholders' main concerns regarding environmental, social, and governance issues[196]. Board and Management Structure - The board consists of four executive directors and three independent non-executive directors as of March 31, 2024[116]. - The company has established a remuneration committee to review and recommend compensation policies for directors and senior management based on performance and market comparisons[88]. - The company has appointed at least three independent non-executive directors as required by GEM listing rules, and established an audit committee with a majority of independent members[133]. - The company has a clear division of responsibilities between the board and management to maintain control over key decisions[119].

Financial Performance - The company's revenue for the six months ended September 30, 2023, was HKD 24,555,000, representing a 22.0% increase compared to HKD 20,021,000 for the same period last year[4]. - The company reported a loss before tax of HKD 2,145,000 for the six months ended September 30, 2023, which is a 35.7% reduction from a loss of HKD 3,331,000 in the same period last year[4]. - The total comprehensive loss for the six months ended September 30, 2023, was HKD 2,099,000, down from HKD 3,277,000 in the previous year, reflecting a 36.0% improvement[16]. - The company reported a net loss attributable to shareholders of HKD 2,123 thousand for the six months ended September 30, 2023, compared to a loss of HKD 3,305 thousand for the same period in 2022, representing a 35.7% improvement[33]. - Revenue from medical consultation services increased to HKD 589 thousand, up 18.7% from HKD 496 thousand in the previous year[26]. - Total revenue for the six months ended September 30, 2023, was HKD 24,555 thousand, a 22.0% increase compared to HKD 20,021 thousand in the same period of 2022[26]. - The basic loss per share for the six months ended September 30, 2023, was HKD 0.54, compared to HKD 0.83 for the same period last year, showing an improvement in per-share loss metrics[16]. - The company's basic loss per share for the period was HKD 0.54, a reduction of 34.9% from HKD 0.83 in the previous year[73]. Cash Flow and Assets - The operating cash generated for the three months ended September 30, 2023, was HKD 2,831,000, compared to HKD 862,000 for the same period in 2022, indicating a significant improvement[10]. - The company's cash and cash equivalents at the end of the reporting period were HKD 3,351,000, a decrease from HKD 9,751,000 at the end of the previous year[10]. - As of September 30, 2023, total assets amounted to HKD 24,912 thousand, a decrease of 6.7% from HKD 26,713 thousand as of March 31, 2023[18]. - The company reported a decrease in total liabilities to HKD 28,681 thousand as of September 30, 2023, down from HKD 29,291 thousand as of March 31, 2023[18]. - The net asset value as of September 30, 2023, was HKD 9,037 thousand, a decline of 19.0% from HKD 11,160 thousand as of March 31, 2023[18]. - The group’s bank balance and cash as of September 30, 2023, was HKD 3.4 million, a decrease from HKD 5.0 million as of March 31, 2023, with no external borrowings[130]. - Time deposits amounted to HKD 13.6 million as of September 30, 2023, slightly down from HKD 13.9 million as of March 31, 2023[131]. Liabilities and Equity - The net current liabilities of the group were HKD 3.8 million, primarily due to contract liabilities of HKD 18.5 million, which are expected to be fulfilled without cash outflow[12]. - The net current liabilities of the group as of September 30, 2023, stood at HKD 3.8 million, an increase from HKD 2.6 million as of March 31, 2023[130]. - As of September 30, 2023, the total equity of the group was HKD 9.0 million, down from HKD 11.2 million as of March 31, 2023[130]. - The company has no interest-bearing borrowings, resulting in a capital debt ratio of zero as of September 30, 2023[76]. Operational Highlights - The company continues to focus on providing medical consultation services, prescription and dispensing services, and treatment services as its primary revenue sources[13]. - The group operates a single business segment focused on medical consultation services, prescription and dispensing services, and treatment services[46]. - The group operates two "Medicskin" brand medical skin care centers in prime locations in Hong Kong, focusing on treating skin diseases and improving customer appearance[67]. - The group continues to face intense competition and rising operational costs, impacting consumer sentiment amid ongoing economic challenges[45]. Employee and Costs - Employee costs increased to HKD 12,511 thousand for the six months ended September 30, 2023, up from HKD 10,420 thousand in the previous year, reflecting a 20.0% rise[30]. - The group employed 28 full-time and 16 part-time employees as of September 30, 2023, with total employee costs amounting to HKD 12.5 million for the six months ended September 30, 2023, compared to HKD 10.4 million for the same period in 2022[115]. - Employee costs rose by HKD 2.1 million or 20.1% to HKD 12.5 million, primarily due to increased salaries and performance bonuses linked to revenue growth[92]. Governance and Compliance - The company has maintained its accounting policies consistent with those used in the preparation of the financial statements for the year ended March 31, 2023[11]. - The audit committee reviewed the group's unaudited interim financial statements for the six months ended September 30, 2023, and found them compliant with applicable accounting standards and GEM listing rules[111]. - The company has adopted corporate governance practices in accordance with the GEM listing rules and has complied with them during the reporting period[108]. - The board of directors believes that the current structure does not undermine the balance of power and authority between the board and the management of the group[119]. Future Outlook - The company remains cautiously optimistic about future performance, anticipating a recovery in sales due to the resumption of normal social and economic activities[90]. - The company anticipates that the application of new accounting standards will not have a significant impact on its financial statements in the foreseeable future[23]. Dividends and Share Options - The company did not declare an interim dividend for the six months ended September 30, 2023, consistent with the previous year[32]. - The company has adopted a share option scheme since December 3, 2014, to reward and/or incentivize eligible individuals for their contributions to the group[115]. - There were no share options granted, exercised, lapsed, or cancelled during the six months ended September 30, 2023[122]. Related Party Transactions - The group has not entered into any transactions with related parties during the six months ended September 30, 2023[43]. - The group reported no individual customer contributing over 10% of total revenue during the six months ended September 30, 2023[48].

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：8307） 截至2023年9月30日止六個月之 中期業績公告 密迪斯肌控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然公佈本公司及其附 屬公司（統稱「本集團」）截至2023年9月30日止六個月之未經審核簡明綜合中期業績連同 去年同期之未經審核比較數字。本公告載有本公司2023/24中期報告全文，符合聯交所 GEM證券上市規則（「GEM上市規則」）有關隨附中期業績初步公告的資料的相關規定。 本公告刊載於聯交所網站(www.hkexnews.hk)及本公司網站(www.medicskinholdings.com)。 本公司2023/24中期報告印刷本將適時寄發予本公司股東，並於本公司及聯交所網站可供查 閱。 承董事會命 密迪斯肌控股有限公司 主席兼執行董事 江覺亮醫生 ...

Financial Performance - The company reported a revenue of HKD 12,912 thousand for the three months ended June 30, 2023, representing a 23.3% increase from HKD 10,467 thousand in the same period of 2022[4] - The loss before tax for the period was HKD 550 thousand, compared to a loss of HKD 799 thousand in the previous year, indicating a 30.9% improvement[4] - The basic and diluted loss per share was HKD 0.14, an improvement from HKD 0.20 in the same quarter of the previous year[4] - The total comprehensive loss for the period was HKD 530 thousand, compared to HKD 792 thousand in the previous year, showing a 33.0% reduction[6] - The company reported a loss attributable to owners of the company of HKD 539 million for the three months ended June 30, 2023, compared to a loss of HKD 786 million for the same period in 2022, representing a 31.5% improvement[26] - The loss attributable to the company's owners for the three months ended June 30, 2023, was HKD 0.5 million, a decrease of HKD 0.3 million or 31.4% from HKD 0.8 million for the same period in 2022[57] - Basic loss per share for the period was HKD 0.14, down 30.0% from HKD 0.20 in the previous year[57] Revenue Breakdown - The revenue from medical consultation services was HKD 303 thousand, up from HKD 225 thousand, reflecting a 34.7% increase year-over-year[9] - The revenue from prescription and dispensing services increased to HKD 2,489 thousand from HKD 2,077 thousand, marking a 19.9% growth[9] - The revenue from treatment services rose to HKD 10,120 thousand, compared to HKD 8,165 thousand, which is a 24.0% increase[9] - Advisory service revenue increased to HKD 167,000 for the three months ended June 30, 2023, up from HKD 51,000 in the same period of 2022, marking a significant increase of 227.5%[22] - The revenue breakdown includes HKD 0.3 million from medical diagnosis services, HKD 2.5 million from prescription and dispensing services, and HKD 10.1 million from treatment services, accounting for 2.3%, 19.3%, and 78.4% of total revenue respectively[60] Operational Insights - The company operates primarily in Hong Kong, with nearly all revenue generated from external customers located there[20] - The company is focused on expanding its services in medical consultation, prescription and dispensing, and treatment services[19] - The company plans to continue market research and evaluation of new products, skills, and treatment technologies to drive business growth and maintain competitiveness[45] - The company maintains a cautious optimism regarding future performance, anticipating a recovery in local consumer sentiment and sales due to the lifting of COVID-19 restrictions and the resumption of cross-border travel with mainland China[58] - The company aims to strengthen its market position and identify new business opportunities to enhance brand development and maximize returns for investors[58] Cost and Expenses - Employee costs rose by HKD 1.4 million or 28.3% to HKD 6.3 million for the three months ended June 30, 2023, primarily due to increased revenue leading to higher salaries and performance bonuses for doctors[47] - Other income, losses, and expenses increased to a net loss of HKD 167,000, up HKD 124,000 or 288.4% from HKD 43,000 in the previous year, primarily due to the absence of government subsidies[61] - Other expenses rose by HKD 0.2 million or 12.0% to HKD 2.0 million, consistent with the increase in revenue[65] - For the three months ended June 30, 2023, the group's cost of used inventory was HKD 2.4 million, compared to HKD 2.0 million for the same period in 2022, representing 18.7% of revenue for both periods[89] Corporate Governance - The company has adopted a share option scheme to reward and/or return contributions from eligible individuals, compliant with GEM Listing Rules Chapter 23[84] - As of June 30, 2023, there were no unexercised share options under the share option scheme[85] - The company is committed to appointing sufficient independent non-executive directors to comply with GEM Listing Rules within three months from June 7, 2023[82] - The board of directors includes both executive and independent non-executive members, ensuring oversight and balance in decision-making processes[87] - The company has acknowledged the need to maintain a positive relationship between executive and non-executive directors to enhance operational efficiency[81] - The board will regularly meet to discuss significant matters affecting the group's operations[81] - The company has confirmed compliance with applicable laws and sufficient disclosures have been made[88] Tax and Liabilities - The company did not incur any tax provisions for Hong Kong profits tax during the periods as there were no estimated taxable profits[66] - The company has a net current liability of HKD 3.0 million as of June 30, 2023, primarily due to contract liabilities of HKD 19.3 million, which are expected to be fulfilled without cash outflow[32] Market Presence - The company operates two "Medicskin" brand medical skin care centers in prime locations in Hong Kong, focusing on treating skin diseases and improving customer appearance[42] - The company has not reported any significant impact from the new Hong Kong Financial Reporting Standards that came into effect on April 1, 2023[7] - The company has no major customers contributing more than 10% of total revenue for the three months ended June 30, 2023, and 2022, indicating a diversified customer base[33]